Evidence map›Paper›PMID 42506612›Full record

ArticleVaccines2026

A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Outer Membrane Vesicle (OMV) Platform-Based Vaccine Administered Intranasally to Healthy Adults.

Heleen Kraan, Anne van der Geest, Dinja Oosterhoff, Corine Kruiswijk, Peter Soema

Abstract read
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Heleen KraanAdJane BV, Thijsseweg 11, 2629 JA Delft, The Netherlands.
Anne van der GeestAthena Institute, Vrije Universiteit, Boelelaan 1105, 1081 HV Amsterdam, The Netherlands.ORCID 0000-0003-0977-8516
Dinja OosterhoffIntravacc BV, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands.ORCID 0000-0001-8707-2266
Corine KruiswijkIntravacc BV, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands.
Peter SoemaIntravacc BV, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands.

Funding

Ministry of Health Welfare and Sport 1006173-PDC19
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

adjuvantintranasal vaccinemucosal immunityNeisseria meningitidisOMVSARS-CoV-2vaccine platform

Identifiers

PMID42506612
PMCPMC13417143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.